Bio-Rad Reports Fourth-Quarter and Full-Year 2015 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Bio-Rad Reports Fourth-Quarter and Full-Year 2015 Financial Results

HERCULES, CA--(Marketwired - Feb 25, 2016) - Bio-Rad Laboratories, Inc. ( NYSE : BIO ) ( NYSE : BIO.B ), a global provider of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2015.

Fourth-quarter 2015 reported revenues were $570.6 million, a decrease of 4.6% compared to $598.2 million reported for the fourth quarter of 2014. On a currency-neutral basis, quarterly revenues increased 2.8% compared to the same period in 2014. Fourth-quarter gross margin was 54.1% compared to 53.1% during the fourth quarter in 2014.

Net income for the fourth quarter of 2015 was $49.5 million, or $1.68 per share on a fully diluted basis, compared to $39.0 million, or $1.34 per share during the same period in 2014. The increase in net income was largely due to lower SG&A and research & development (R&D) expenses as well as a lower effective tax rate in the fourth quarter of 2015 of 8.7%, which was the result of expected utilization of foreign tax credits in the U.S. and the permanent reinstatement of the federal R&D credit in the fourth quarter of 2015. This increase was partially offset by a lower gross profit during the fourth quarter of 2015 compared to the same period in 2014. 

For the full year of 2015, sales were $2,019.4 million compared to $2,175.0 million in 2014, a decrease of 7.2%. On a currency neutral basis, sales increased by 1.6%. Full-year gross margin was 55.5% compared to 54.2% reported in 2014. The gross margin increase compared to 2014 primarily reflected sales mix as well as costs associated with plant closures and a product line discontinuation that occurred in 2014.

Full-year net income in 2015 was $113.1 million, or $3.85 per share on a fully diluted basis, compared to $88.8 million, or $3.05 per share in 2014. The year-over-year net income increase in 2015 was primarily the result of lower SG&A expenses, lower R&D expenses, and the effect of currency in 2015. SG&A in 2014 included approximately $23.7 million in non-recurring expense. The effective tax rate of 22.5% for 2015 compared to 32.5% in 2014 was primarily due to expected utilization of foreign tax credits on certain foreign dividends as well as a reduction in certain tax reserves as statutes lapsed.

"Despite currency headwinds, we are encouraged with our underlying performance in the fourth quarter and the entire year, which reflected good momentum across many of our core product lines," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "Overall, 2015 was a year of progress on many fronts, with continued investment in infrastructure to support our growth now and in the future."

Life Science The Life Science segment net sales for the fourth quarter were $218.1 million, a decrease of 2.5% compared to the same period in 2014. On a currency-neutral basis, Life Science segment sales increased by 3.4%. Results from the fourth quarter benefited from currency-neutral increased sales of the segment's core businesses, in particular, process chromatography media, the Droplet Digital ™ PCR, and cell biology products. Full-year reported revenues for the Life Science segment were $695.0 million, a decrease of 4.6% compared to the same period in 2014. On a currency-neutral basis, full-year sales increased 2.5%. 

Clinical Diagnostics The Clinical Diagnostics segment reported net sales of $348.6 million for the fourth quarter, a decrease of 5.9% compared to the same period in 2014. On a currency-neutral basis, net sales were up 2.5%. Results from the fourth quarter reflected growth across certain product lines, most notably clinical immunology, quality controls, blood testing, and diabetes products. During the fourth quarter, Bio-Rad announced that its D-100 ™ System for A1c testing had obtained clearance from the U.S. Food and Drug Administration (FDA) to monitor the long-term blood glucose control of individuals with diabetes, as an aid in the diagnosis of diabetes, and to help identify those who may be at risk for developing the disease. Also during the fourth quarter, the Company announced that it had received clearance from the FDA for the company's TANGO infinity ® system. The system automates routine blood typing and screening testing procedures for patients and donors. Full-year reported revenues for the Clinical Diagnostics segment were $1,310.4 million, a decrease of 8.5% compared to the same period in 2014. On a currency-neutral basis, full-year sales increased 1.1% compared to 2014.

2015 Full-Year Highlights

  • Full-year, sales were $2,019.4 million compared to $2,175.0 million in 2014. After normalizing for the impact of currency effects, full year revenues increased 1.6%.
  • Year-over-year net income in 2015 was $113.1 million, or $3.85 per share on a fully diluted basis, compared to $88.8 million, or $3.05 per share in 2014.
  • In April, Bio-Rad introduced a new laser configuration for its S3e ™ Cell Sorter, providing new capabilities for stem cell and other research applications. Also that month, Bio-Rad announced the availability in U.S. markets of its BioPlex ®  2200 25-OH Vitamin D kit for use on the company's BioPlex ® 2200 system.
  • In June, Bio-Rad announced that its VARIANT™ II TURBO HbA1c Kit - 2.0 had obtained clearance from the U.S. Food and Drug Administration for use as an aid in diagnosing diabetes and identifying people who may be at risk for developing the disease.
  • In July, Bio-Rad announced that it had received U.S. Food and Drug Administration pre-market approval to offer its BioPlex ®  2200 HIV Ag-Ab assay, the company's 5th generation HIV diagnostic test.
  • In August, Bio-Rad introduced its IH-500, a fully automated random access system for blood typing and screening for small and medium-size transfusion medicine laboratories. The instrument is available in Europe, Asia, Africa, Australia, and Latin America.
  • In December, Bio-Rad received clearance from the FDA for the Company's D-100 System for A1c testing and its TANGO infinity system. 

Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) February 25, 2016. Interested parties may access the call at 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., passcode: 30616978. You may also listen to the conference call via a webcast that is available in the "Investor Relations" section of our website under "Quarterly Results" at www.bio-rad.com . The webcast will be available for up to a year. 

About Bio-Rad Bio-Rad Laboratories, Inc. ( NYSE : BIO ) ( NYSE : BIO.B ) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,700 people worldwide and had revenues exceeding $2 billion in 2015. For more information, please visit www.bio-rad.com .

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our release of new products, sales by region and future financial performance. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, foreign currency exchange fluctuations, difficulties in implementing our global enterprise resource planning system, supply chain issues, our ability to compete effectively, product quality and liability issues, reductions in government funding or capital spending of our customers, international legal and regulatory risks, recent changes to our global organizational structure and executive management team, changes in the healthcare industry, global economic conditions, and natural disasters and other catastrophic events beyond our control. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014, and its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015, and its Annual Report on Form 10-K for the fiscal year ended December 31, 2015 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.

   
Bio-Rad Laboratories, Inc.  
Condensed Consolidated Statements of Income  
   
(in thousands, except per share data)  
(UNAUDITED)  
                         
    Three Months Ended December 31,     Year Ended December 31,  
    2015     2014     2015     2014  
Net sales   $ 570,557     $ 598,224     $ 2,019,441     $ 2,175,044  
  Cost of goods sold     262,042       280,814       897,771       996,527  
Gross profit     308,515       317,410       1,121,670       1,178,517  
                                 
  Selling, general and administrative expense     193,145       207,537       761,990       808,200  
  Research and development expense     55,887       59,287       192,972       220,333  
Income from operations     59,483       50,586       166,708       149,984  
                                 
  Interest expense     6,034       5,000       21,692       22,131  
  Foreign currency exchange losses, net     1,339       3,187       10,249       9,305  
  Other (income) expense, net     (2,088 )     (3,347 )     (11,080 )     (13,009 )
Income before income taxes     54,198       45,746       145,847       131,557  
                                 
  Provision for income taxes     (4,716 )     (6,709 )     (32,754 )     (42,712 )
Net income   $ 49,482     $ 39,037     $ 113,093     $ 88,845  
                                 
Basic earnings per share:                                
  Net income per basic share   $ 1.69     $ 1.35     $ 3.87     $ 3.08  
                                 
  Weighted average common shares - basic     29,321       29,000       29,186       28,876  
                                 
Diluted earnings per share:                                
  Net income per diluted share   $ 1.68     $ 1.34     $ 3.85     $ 3.05  
                                 
  Weighted average common shares - diluted     29,470       29,192       29,409       29,133  
                                 
                                 
 
Bio-Rad Laboratories, Inc.
Condensed Consolidated Balance Sheets
 
(in thousands)
(UNAUDITED)
           
    December 31,   December 31,
    2015   2014
             
Current assets:            
  Cash and cash equivalents   $ 457,549   $ 413,251
  Short-term investments     332,928     284,384
  Accounts receivable, net     391,485     377,640
  Inventories, net     490,224     470,997
  Other current assets     105,410     170,095
    Total current assets     1,777,596     1,716,367
             
Property, plant and equipment, net     437,690     428,836
Goodwill, net     495,948     500,441
Purchased intangibles, net     214,026     254,228
Other investments     719,840     389,309
Other assets     66,442     52,097
    Total assets   $ 3,711,542   $ 3,341,278
             
             
Current liabilities:            
  Accounts payable, accrued payroll and employee benefits   $ 280,248   $ 282,034
  Current maturities of long-term debt     298     265
  Income and other taxes payable     29,339     35,165
  Other current liabilities     131,466     129,297
    Total current liabilities     441,351     446,761
             
Long-term debt, net of current maturities     435,707     435,710
Other long-term liabilities     343,981     273,652
    Total liabilities     1,221,039     1,156,123
                 
    Total stockholders' equity     2,490,503     2,185,155
    Total liabilities and stockholders' equity   $ 3,711,542   $ 3,341,278
                 
                 
   
Bio-Rad Laboratories, Inc.  
Condensed Consolidated Statements of Cash Flows  
   
(in thousands)  
(UNAUDITED)  
             
    Year Ended December 31,  
             
    2015     2014  
                 
Cash flows from operating activities:                
  Cash received from customers   $ 1,956,084     $ 2,162,520  
  Cash paid to suppliers and employees     (1,730,062 )     (1,806,526 )
  Interest paid     (20,793 )     (20,793 )
  Income tax payments     (31,715 )     (28,939 )
  Settlement to the SEC and DOJ relating to the FCPA, including interest     -       (55,050 )
  Other operating activities     12,696       22,100  
  Net cash provided by operating activities     186,210       273,312  
                 
Cash flows from investing activities:                
  Payments for acquisitions and long-term investments     (4,356 )     (44,627 )
  Other investing activities     (162,513 )     (145,884 )
  Net cash used in investing activities     (166,869 )     (190,511 )
                 
Cash flows from financing activities:                
  Payments on long-term borrowings     (282 )     (253 )
  Other financing activities     8,863       11,942  
  Net cash provided by financing activities     8,581       11,689  
                 
Effect of foreign exchange rate changes on cash     16,376       (12,790 )
                 
Net increase in cash and cash equivalents     44,298       81,700  
Cash and cash equivalents at beginning of year     413,251       331,551  
Cash and cash equivalents at end of year   $ 457,549     $ 413,251  
                 
                 
Reconciliation of net income to net cash provided by operating activities:                
Net income   $ 113,093     $ 88,845  
Adjustments to reconcile net income to net cash provided by operating activities:                
  Depreciation and amortization     131,848       149,889  
  Changes in working capital     (51,821 )     21,700  
  Other     (6,910 )     12,878  
Net cash provided by operating activities   $ 186,210     $ 273,312  
                 

Investor and Financial Contacts: Christine Tsingos Executive Vice President and Chief Financial Officer Ron Hutton Vice President and Treasurer Bio-Rad Laboratories, Inc. 510-724-7000 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vail’s Board Fight Puts Strategy Under a Sharp Lens

Updated Category News Views 62

Fresh snow does not make a boardroom dispute disappear. Vail Resorts has put out an investor presentation ahead of its December 14, 2026 annual meeting, asking shareholders to support all nine of management’s director nominees on its white proxy card. That is the formal message. The real message is plainer: NYSE:MTN knows this election has become a test of whether...

Continue Reading
Color Me Mine Tests Florida's Creative Leisure Demand

Updated Category News Views 72

Pottery studios are not exactly the sort of thing that makes markets pound the table, but Florida’s latest Color Me Mine push deserves a closer look. The company signed three franchise agreements in 2026 for Panama City Beach, Doral and Boca Raton, adding planned growth to a state where it already operates 11 studios. For a private franchisor, this is not a quarterly...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 151

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 74

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Watson Motion Tests Military Pretrial Confinement Rules

Updated Category News Views 170

Military confinement fights are rarely neat, and this one comes with a short clock but plenty of unanswered questions. Defense lawyers for U.S. Air Force Maj. Jason Watson argued on Nov. 17 that he should be released from pretrial confinement while his case proceeds. A military judge is ordinarily expected to issue a ruling within 14 days of the hearing, under the court's...

Continue Reading
AI Gives CPA Firms a New Advisory Staffing Math Today

Updated Category News Views 75

Month-end just got a lot less comfortable for firms living on the clock. Netsurit and Southwestern Talent are pitching the Virtual CFO Platform as a way for CPA firms to turn machine-led analysis into advisory work without first building a costly bench of specialists. That is not a cute workflow tweak. It goes straight at the labor model that has kept plenty of accounting...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 175

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Hitachi's Quiet Fusion Bet Is Really About Data Control

Updated Category News Views 69

Weeks of engineering work can vanish because one storage system hiccups, which is a rotten way to learn that data infrastructure belongs in the mission-critical column. Esteyco’s new environment, built with Hitachi Vantara and implemented by Quadrics Sistemas, is not a fusion breakthrough. It is the less glamorous machinery that keeps serious fusion research from...

Continue Reading
Emaar's Huspy Deal Brings Financing Into Home Sales

Updated Category News Views 87

Mortgage paperwork is nobody’s idea of luxury, yet it can wreck a property sale faster than a bad floor plan. Emaar Properties has partnered with Dubai-based Huspy to give its customers access to mortgage advice and financing comparisons from more than 20 UAE banks. It is not a flashy tower launch or a headline-grabbing land purchase. Frankly, that is why investors...

Continue Reading
RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 160

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading

Top 5 Most Recently Viewed Articles

How the Bank of England's Interest Rate Decision Impacts Your Investments

Updated Category Economy Views 316

Introduction The Bank of England's decision on interest rates plays a critical role in shaping the economic landscape, with far-reaching effects on your investment portfolio. Changes in these rates can influence stock market performance, affect bond yields, and alter the attractiveness of various asset classes. Understanding how these adjustments can impact your...

Continue Reading
Eric Beightel Joins Environmental Science Associates Team

Updated Category News Views 131

Eric Beightel Appointed as Federal Strategy Director Environmental Science Associates (ESA) is thrilled to welcome Eric Beightel to its team as the new Federal Strategy Director. With a comprehensive background in environmental policy, Beightel brings a wealth of knowledge to ESA, poised to enhance its capabilities in navigating the complexities of federal regulations....

Continue Reading
iBio Inc. Showcases Innovative Antibody Developments Soon

Updated Category News Views 257

Exciting Presentations from iBio Inc. iBio, Inc. (NASDAQ: IBIO), a pioneering biotechnology company, is gearing up to present breakthrough research on its Activin E antibody. This development showcases its commitment to addressing critical health challenges like obesity. Recently, Cory Schwartz, Ph.D., the Director of Research and Early Development at iBio, announced his...

Continue Reading
Turkey's Markets Experience A Dip as Investors React

Updated Category News Views 319

A Dip in Turkey's Stock Market Performance Turkey's stock market witnessed a decline recently, with shares closing lower on the exchange. The BIST 100 index, a benchmark for investors, finished down by 0.60%, indicating a challenging trading day for stakeholders. Sectors Impacting Market Trends Leading the Declines A noticeable drop in market values was driven by several...

Continue Reading
Medline Celebrated for Innovation in Respiratory Care Solutions

Updated Category News Views 180

Medline secured the prestigious Zenith Award from the American Association for Respiratory Care (AARC) in 2024, marking a significant moment for traders and healthcare pros alike. This award wasn’t just handed out; it was earned by only eight companies out of over 300 nominees. The kind of spotlight that draws attention can shake up market sentiments. Why Medline Stood...

Continue Reading